Bevacizumab/iodine 125
- PDF / 169,984 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 0 Downloads / 195 Views
1 S
Rectourethral fistula: case report A 75-year-old man developed rectourethral fistula following treatment with bevacizumab for recurrent cecum cancer and iodine-125 for prostate brachytherapy to treat prostate cancer [routes, dosages and time to reaction onset not stated]. The man presented to hospital due to urinary retention and fecaluria. He had been receiving bevacizumab, capecitabine and oxaliplatin [CapeOX regimen] for 1 year to treat recurrent cecum cancer. He had undergone laparoscopic ileocecal resection for cecum cancer 1.5 years earlier, and the final stage had been stage IIIa at that time. Eight months after the operation, recurrence of cecum cancer was noted. He had a history of prostate cancer, hypertension and angina. He had received iodine-125 low-dose-rate prostate brachytherapy for prostate cancer 17 years earlier. On presentation, investigations revealed the following: WBC count 12800 /µL, haemoglobin 6.7 g/dL, CRP 15.55 mg/dL, urea nitrogen 23 mg/dL, creatinine 1.07 mg/dL, total protein 7.1 g/dL, albumin 2.4 g/dL and carcinoembryonic antigen 6.4 ng/mL. An abdominal pelvic CT demonstrated air bubbles from the rectum to the prostate and urethra, multiple liver metastases, lymph nodes metastases and peritoneal dissemination. To prevent urinary tract infection, the man underwent laparoscopic transverse colostomy and percutaneous cystostomy. Subsequently, his quality of life improved; however, his performance status was found to be remarkably decreased. Therefore, he was transferred to another hospital and received the best supportive care [details not stated]. Inoue Y, et al. Rectourethral fistula during bevacizumab administration for cecum cancer after prostate brachytherapy: A case report. Acta Medica Nagasakiensia 64: 35-37, 803507267 No. 1, 2020
0114-9954/20/1826-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 17 Oct 2020 No. 1826
Data Loading...
